Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Novel nanomedicine inhibits progression of pancreatic cancer in mice: Survival rates in pancreatic cancer linked to inverse correlation between specific oncogene and tumor suppressant, Tel Aviv University researchers say

Abstract:
A new Tel Aviv University study pinpoints the inverse correlation between a known oncogene -- a gene that promotes the development of cancer -- and the expression of an oncosuppressor microRNA as the reason for extended pancreatic cancer survival. The study may serve as a basis for the development of an effective cocktail of drugs for this deadly disease and other cancers.

Novel nanomedicine inhibits progression of pancreatic cancer in mice: Survival rates in pancreatic cancer linked to inverse correlation between specific oncogene and tumor suppressant, Tel Aviv University researchers say

New York, NY | Posted on January 3rd, 2018

The study, which was published in Nature Communications, was led by Prof. Ronit Satchi-Fainaro, Chair of the Department of Physiology and Pharmacology at TAU's Sackler Faculty of Medicine, and conducted by Hadas Gibori and Dr. Shay Eliyahu, both of Prof. Satchi-Fainaro's multidisciplinary laboratory, in collaboration with Prof. Eytan Ruppin of TAU's Computer Science Department and the University of Maryland and Prof. Iris Barshack and Dr. Talia Golan of Chaim Sheba Medical Center, Tel Hashomer.

Pancreatic cancer is among the most aggressive cancers known today. The overwhelming majority of pancreatic cancer patients die within just a year of diagnosis. "Despite all the treatments afforded by modern medicine, some 75% of all pancreatic cancer patients die within 12 months of diagnosis, including many who die within just a few months," Prof. Satchi-Fainaro says.

"But around seven percent of those diagnosed will survive more than five years. We sought to examine what distinguishes the survivors from the rest of the patients," Prof. Satchi-Fainaro continues. "We thought that if we could understand how some people live several years with this most aggressive disease, we might be able to develop a new therapeutic strategy."

Calling a nano-taxi

The research team examined pancreatic cancer cells and discovered an inverse correlation between the signatures of miR-34a, a tumor suppressant, and PLK1, a known oncogene. The levels of miR-34a were low in pancreatic cancer mouse models, while the levels of the oncogene were high. This correlation made sense for such an aggressive cancer. But the team needed to see if the same was true in humans.

The scientists performed RNA profiling and analysis of samples taken from pancreatic cancer patients. The molecular profiling revealed the same genomic pattern found earlier in mouse models of pancreatic cancer.

The scientists then devised a novel nanoparticle that selectively delivers genetic material to a tumor and prevents side effects in surrounding healthy tissues.

"We designed a nanocarrier to deliver two passengers: (1) miR-34a, which degrades hundreds of oncogenes; and (2) a PLK1 small interfering RNA (siRNA), that silences a single gene," Prof. Satchi-Fainaro says. "These were delivered directly to the tumor site to change the molecular signature of the cancer cells, rendering the tumor dormant or eradicating it altogether.

"The nanoparticle is like a taxi carrying two important passengers," Prof. Satchi-Fainaro continues. "Many oncology protocols are cocktails, but the drugs usually do not reach the tumor at the same time. But our 'taxi' kept the 'passengers' -- and the rest of the body -- safe the whole way, targeting only the tumor tissue. Once it 'parked,' an enzyme present in pancreatic cancer caused the carrier to biodegrade, allowing the therapeutic cargo to be released at the correct address -- the tumor cells."

Improving the odds

To validate their findings, the scientists injected the novel nanoparticles into pancreatic tumor-bearing mice and observed that by balancing these two targets -- bringing them to a normal level by increasing their expression or blocking the gene responsible for their expression -- they significantly prolonged the survival of the mice.

"This treatment takes into account the entire genomic pattern, and shows that affecting a single gene is not enough for the treatment of pancreatic cancer or any cancer type in general," according to Prof. Satchi-Fainaro.

###

Research for the study was funded by the European Research Council (ERC), Tel Aviv University's Cancer Biology Research Center (CBRC) and the Israel Science Foundation (ISF).

####

About American Friends of Tel Aviv University
American Friends of Tel Aviv University (AFTAU) supports Israel's most influential, comprehensive and sought-after center of higher learning, Tel Aviv University (TAU). TAU is recognized and celebrated internationally for creating an innovative, entrepreneurial culture on campus that generates inventions, startups and economic development in Israel. For three years in a row, TAU ranked 9th in the world, and first in Israel, for alumni going on to become successful entrepreneurs backed by significant venture capital, a ranking that surpassed several Ivy League universities. To date, 2,400 patents have been filed out of the University, making TAU 29th in the world for patents among academic institutions.

For more information, please click here

Contacts:
George Hunka

212-742-9070

Copyright © American Friends of Tel Aviv University

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

RELATED JOURNAL ARTICLE:

Related News Press

News and information

Iranian Firm Offering Nano-Products on Chinese Market October 16th, 2018

Big award enables study of small surfaces: Rice U.'s Matt Jones wins Packard Fellowship to view nanoscale chemical reactions October 15th, 2018

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 October 15th, 2018

TUBALL single wall carbon nanotubes: No ecotoxicity found, unlike other carbon nanotubes October 12th, 2018

Cancer

Nano Pharmaceutical Developed to Target Cancer Cells October 10th, 2018

Scientists use nanoparticles to improve chemotherapy response, boost anti-tumor immunity: U of T scientists use nanoparticles to improve chemotherapy response and boost anti-tumor immunity in breast cancer October 2nd, 2018

Rice U. lab probes molecular limit of plasmonics: Optical effect detailed in organic molecules with fewer than 50 atoms September 5th, 2018

Polymer antibodies efficiently target and eliminate cancer cells August 27th, 2018

Possible Futures

Iranian Firm Offering Nano-Products on Chinese Market October 16th, 2018

Graphene shows unique potential to exceed bandwidth demands of future telecommunications October 12th, 2018

High-performance self-assembled catalyst for SOFC October 12th, 2018

180 Degree Capital Corp. Announces New Portfolio Holdings Airgain, Inc., EMCORE Corporation, Lantronix, Inc. and PDL BioPharma, Inc. October 12th, 2018

Nanomedicine

Big award enables study of small surfaces: Rice U.'s Matt Jones wins Packard Fellowship to view nanoscale chemical reactions October 15th, 2018

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 October 15th, 2018

180 Degree Capital Corp. Announces New Portfolio Holdings Airgain, Inc., EMCORE Corporation, Lantronix, Inc. and PDL BioPharma, Inc. October 12th, 2018

Tracking a Killer: UCSB, UCSD and SBP researchers trace the complex and variable pathways to the deadly condition known as sepsis October 12th, 2018

Discoveries

Researchers quickly harvest 2-D materials, bringing them closer to commercialization: Efficient method for making single-atom-thick, wafer-scale materials opens up opportunities in flexible electronics October 12th, 2018

Graphene shows unique potential to exceed bandwidth demands of future telecommunications October 12th, 2018

High-performance self-assembled catalyst for SOFC October 12th, 2018

Tracking a Killer: UCSB, UCSD and SBP researchers trace the complex and variable pathways to the deadly condition known as sepsis October 12th, 2018

Announcements

Iranian Firm Offering Nano-Products on Chinese Market October 16th, 2018

Big award enables study of small surfaces: Rice U.'s Matt Jones wins Packard Fellowship to view nanoscale chemical reactions October 15th, 2018

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 October 15th, 2018

TUBALL single wall carbon nanotubes: No ecotoxicity found, unlike other carbon nanotubes October 12th, 2018

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers

Big award enables study of small surfaces: Rice U.'s Matt Jones wins Packard Fellowship to view nanoscale chemical reactions October 15th, 2018

Graphene shows unique potential to exceed bandwidth demands of future telecommunications October 12th, 2018

High-performance self-assembled catalyst for SOFC October 12th, 2018

Tracking a Killer: UCSB, UCSD and SBP researchers trace the complex and variable pathways to the deadly condition known as sepsis October 12th, 2018

Nanobiotechnology

Big award enables study of small surfaces: Rice U.'s Matt Jones wins Packard Fellowship to view nanoscale chemical reactions October 15th, 2018

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 October 15th, 2018

180 Degree Capital Corp. Announces New Portfolio Holdings Airgain, Inc., EMCORE Corporation, Lantronix, Inc. and PDL BioPharma, Inc. October 12th, 2018

Tracking a Killer: UCSB, UCSD and SBP researchers trace the complex and variable pathways to the deadly condition known as sepsis October 12th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project